Astellas Pharma and CoMentis Sign $760M Alzheimer’s Deal

Astellas Pharma, Inc. and CoMentis, Inc. announced today that the companies have entered into an agreement to develop products from CoMentis’ beta-secretase inhibitor program, including the recently initiated, phase 2, lead candidate compound CTS-21166, an oral beta-secretase inhibitor for the treatment of Alzheimer’s disease. The agreement also includes a research collaboration to develop additional beta-secretase [...]